

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/024,701	10/024,701 12/17/2001		Dennis Keith	13764-003001	6796	
26161	7590	02/09/2004		EXAM	EXAMINER	
FISH & RIC		SON PC	PESELE	PESELEV, ELLI		
225 FRANK BOSTON, N		0		ART UNIT	PAPER NUMBER	
2001011, 1				1623	1623	

DATE MAILED: 02/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		T & 1: 4: NI	A 1: 4/ - \				
		Application No.	Applicant(s)				
	Office Action Summary	10/024,701	KEITH ET AL.				
	Onice Action Summary	Examiner	Art Unit				
	- The MAILING DATE of this communication ap	Elli Peselev	1623				
Period for	r Reply						
THE N - Extens after S - If the p - If NO p - Failure Any re	DRTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.1 (SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a repleteriod for reply is specified above, the maximum statutory period to reply within the set or extended period for reply will, by statute to the ply received by the Office later than three months after the mailing digital patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be tin ly within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1) 🗌 🖠	Responsive to communication(s) filed on						
2a) ☐ ⁻	This action is FINAL . 2b)⊠ This	s action is non-final.					
, —	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition	on of Claims						
5)	Claim(s) <u>1-57</u> is/are pending in the application ha) Of the above claim(s) is/are withdra Claim(s) is/are allowed. Claim(s) <u>1-57</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/o	own from consideration.					
Application	on Papers	·					
9)∐ Т	The specification is objected to by the Examino	er.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correc The oath or declaration is objected to by the E	·					
Priority u	nder 35 U.S.C. § 119						
a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document Certified copies of the priority document Copies of the certified copies of the priority document application from the International Bureate the attached detailed Office action for a list	ts have been received. ts have been received in Applicationity documents have been receive au (PCT Rule 17.2(a)).	ion No ed in this National Stage				
Attachment((s) e of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)				
2) Notice 3) Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail D					

Application/Control Number: 10/024,701

Art Unit: 1623

Claims 1-21 and 36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

It is not clear what is meant by the terminology "a cation from a salt" (claim 1).

It is not clear what is encompassed by the terminology "calcium acetate pH 6.1" (claim 36).

Claims 22-57 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for glycerol, does not reasonably provide enablement for polyhydric alcohol. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The terminology "polyhydric alcohol" (claims 22, 29 and 53) is not limited to an alcohol having any specific weight or chain length and therefore encompasses an alcohol having 100 or more carbon atoms. There is a good reason to doubt that such an alcohol will be useful in the claimed methods.

Claims 1-3 and 5-21 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for polyethylene glycol or polyethylene glycol monomethyl ether, does not reasonably provide enablement for an organic precipitant. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The terminology "an organic precipitant" (claim 1) encompasses a large number of organic compounds. Since the specification fails to provide any guidance on how to choose the desired precipitants, it would take an undue

Application/Control Number: 10/024,701

Art Unit: 1623

amount of experimentation to determine which specific organic precipitant, with the exception of polyethylene glycol or polyethylene glycol monomethyl ether, will be useful in the instant invention.

Claims 51-52 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim a multiple dependent claim cannot depend from any other multiple dependent claims. See MPEP § 608.01(n).

Note that claims 51-52 depend from claim 46 which depends from claims 22 and 29.

Abbott et al (U.S. Patent No. 4,524,135), which discloses A-21978C cyclic peptides, including daptomycin and Schwartz et al (U.S. Patent No. 5,336,756), which discloses crystallization of cyclic lipopeptides are cited to show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-2751. The examiner can normally be reached on 9.00-5.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached on (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 4

Application/Control Number: 10/024,701

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elli Peselev

ELLI PESELEV PRIMARY EXAMINER GROUP 1200